• Something wrong with this record ?

[18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast Cancer

PM. Manohar, LM. Peterson, IC. Jenkins, QV. Wu, BF. Kurland, A. Novakova-Jiresova, M. Muzi, DL. Chen, JM. Specht, S. Dintzis, PE. Kinahan, DA. Mankoff, HM. Linden

. 2025 ; 27 (3) : 410-420. [pub] 20250514

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25015435

Grant support
R50 CA211270 NCI NIH HHS - United States

AIM: This study examines the combination of FES-PET and FDG-PET as complementary imaging for detection of metastatic ILC. METHODS: We retrospectively evaluated FES and FDG uptake in patients with metastatic ILC from an estrogen receptor (ER) positive primary tumor. We classified lesions into three categories (FES high/FDG low, FES high/FDG high, FES low/FDG low) using SUVmax cut-off values of 1.5 for FES and 5.0 for FDG. Qualitative evaluation included examination of the difference in the extent of disease between FES and FDG. RESULTS: Of the 38 patients, 82% had FES uptake in all tumor sites identified by FDG, with 18% lacking FES uptake in at least one lesion. Mean (range) SUVmax for FES and FDG was 4.0 (0.67-10.6) and 4.6 (1.3-12.5), respectively. The majority of ILC patients (25/38), had lesions with FES high/FDG low uptake, consistent with the strongly ER + indolent nature of ILC. Patients with disease classified as FES high/FDG low had longer median overall survival (OS) (3.2 years) and progression-free survival (PFS) (1.5 years) than FES high/FDG high (OS = 2.1 years and PFS = 0.46 years). The median overall OS for all patients was 3.0 years (95% CI 2.5, 4.8) and PFS of 1.3 years (95% CI 0.6, 2.5). 8 patients (21%) had qualitatively more extensive disease by FES-PET. CONCLUSIONS: Our findings suggest that both FES-PET and FDG-PET can identify metastatic ILC and be useful in detecting the pattern and extent of disease. The imaging combination provides additional information for prognosis and clinical decision making, balancing suitability for endocrine therapy and aggressiveness/indolence of disease.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015435
003      
CZ-PrNML
005      
20250731090956.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11307-025-02015-2 $2 doi
035    __
$a (PubMed)40369385
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Manohar, Poorni M $u University of Washington, Seattle, WA, USA $u Fred Hutchinson Cancer Research Center, FHCC 1144 Eastlake (LG-200), Seattle, WA, 98109-1023, USA
245    10
$a [18 F]-Fluoroestradiol PET (FES-PET) and [18 F] Flurodeoxyglucose PET (FDG-PET) Imaging May Aid in Managing Therapy in Patients with Metastatic Lobular Breast Cancer / $c PM. Manohar, LM. Peterson, IC. Jenkins, QV. Wu, BF. Kurland, A. Novakova-Jiresova, M. Muzi, DL. Chen, JM. Specht, S. Dintzis, PE. Kinahan, DA. Mankoff, HM. Linden
520    9_
$a AIM: This study examines the combination of FES-PET and FDG-PET as complementary imaging for detection of metastatic ILC. METHODS: We retrospectively evaluated FES and FDG uptake in patients with metastatic ILC from an estrogen receptor (ER) positive primary tumor. We classified lesions into three categories (FES high/FDG low, FES high/FDG high, FES low/FDG low) using SUVmax cut-off values of 1.5 for FES and 5.0 for FDG. Qualitative evaluation included examination of the difference in the extent of disease between FES and FDG. RESULTS: Of the 38 patients, 82% had FES uptake in all tumor sites identified by FDG, with 18% lacking FES uptake in at least one lesion. Mean (range) SUVmax for FES and FDG was 4.0 (0.67-10.6) and 4.6 (1.3-12.5), respectively. The majority of ILC patients (25/38), had lesions with FES high/FDG low uptake, consistent with the strongly ER + indolent nature of ILC. Patients with disease classified as FES high/FDG low had longer median overall survival (OS) (3.2 years) and progression-free survival (PFS) (1.5 years) than FES high/FDG high (OS = 2.1 years and PFS = 0.46 years). The median overall OS for all patients was 3.0 years (95% CI 2.5, 4.8) and PFS of 1.3 years (95% CI 0.6, 2.5). 8 patients (21%) had qualitatively more extensive disease by FES-PET. CONCLUSIONS: Our findings suggest that both FES-PET and FDG-PET can identify metastatic ILC and be useful in detecting the pattern and extent of disease. The imaging combination provides additional information for prognosis and clinical decision making, balancing suitability for endocrine therapy and aggressiveness/indolence of disease.
650    _2
$a lidé $7 D006801
650    12
$a fluorodeoxyglukosa F18 $x chemie $7 D019788
650    _2
$a ženské pohlaví $7 D005260
650    12
$a nádory prsu $x diagnostické zobrazování $x patologie $x terapie $7 D001943
650    _2
$a lidé středního věku $7 D008875
650    12
$a pozitronová emisní tomografie $x metody $7 D049268
650    _2
$a senioři $7 D000368
650    _2
$a dospělí $7 D000328
650    12
$a estradiol $x analogy a deriváty $x chemie $7 D004958
650    _2
$a metastázy nádorů $7 D009362
650    12
$a lobulární karcinom $x diagnostické zobrazování $x terapie $x patologie $7 D018275
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a senioři nad 80 let $7 D000369
655    _2
$a časopisecké články $7 D016428
700    1_
$a Peterson, Lanell M $u University of Washington, Seattle, WA, USA. lanell@uw.edu $u Fred Hutchinson Cancer Research Center, FHCC 1144 Eastlake (LG-200), Seattle, WA, 98109-1023, USA. lanell@uw.edu $1 https://orcid.org/0000000216135909
700    1_
$a Jenkins, Isaac C $u Fred Hutchinson Cancer Research Center, FHCC 1144 Eastlake (LG-200), Seattle, WA, 98109-1023, USA
700    1_
$a Wu, Qian Vicky $u Fred Hutchinson Cancer Research Center, FHCC 1144 Eastlake (LG-200), Seattle, WA, 98109-1023, USA
700    1_
$a Kurland, Brenda F $u GSK, Philadelphia, PA, USA
700    1_
$a Novakova-Jiresova, Alena $u Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Muzi, Mark $u University of Washington, Seattle, WA, USA
700    1_
$a Chen, Delphine L $u University of Washington, Seattle, WA, USA $u Fred Hutchinson Cancer Research Center, FHCC 1144 Eastlake (LG-200), Seattle, WA, 98109-1023, USA
700    1_
$a Specht, Jennifer M $u University of Washington, Seattle, WA, USA $u Fred Hutchinson Cancer Research Center, FHCC 1144 Eastlake (LG-200), Seattle, WA, 98109-1023, USA
700    1_
$a Dintzis, Suzanne $u University of Washington, Seattle, WA, USA $u Fred Hutchinson Cancer Research Center, FHCC 1144 Eastlake (LG-200), Seattle, WA, 98109-1023, USA
700    1_
$a Kinahan, Paul E $u University of Washington, Seattle, WA, USA $u Fred Hutchinson Cancer Research Center, FHCC 1144 Eastlake (LG-200), Seattle, WA, 98109-1023, USA
700    1_
$a Mankoff, David A $u University of Pennsylvania, Philadelphia, PA, USA
700    1_
$a Linden, Hannah M $u University of Washington, Seattle, WA, USA $u Fred Hutchinson Cancer Research Center, FHCC 1144 Eastlake (LG-200), Seattle, WA, 98109-1023, USA
773    0_
$w MED00008643 $t Molecular imaging and biology $x 1860-2002 $g Roč. 27, č. 3 (2025), s. 410-420
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40369385 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090950 $b ABA008
999    __
$a ok $b bmc $g 2366330 $s 1252560
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 27 $c 3 $d 410-420 $e 20250514 $i 1860-2002 $m Molecular imaging and biology $n Mol Imaging Biol $x MED00008643
GRA    __
$a R50 CA211270 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options